Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 12, Issue 6, 1999, Pages 407-412

  Velussi, Mario ^a,b   Cernigoi, A M ^a   Tortul, C ^a   Merni, M ^a  

^a Diabetology Dept Monfalcone/Gorizia   (Italy)

^b NONE   (Italy)

Author keywords

Atorvastatin; Dyslipidaemia; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLIBENCLAMIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PYRROLES; TRIGLYCERIDES;

EID: 0033387438     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. United Kingdom Prospective Diabetes Study: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). B.M.J. 316: 823-828, 1998.
2. Malmberg K., Ryden I.: Myocardial infarction in patients with diabetes mellitus. Eur. Heart J. 9: 256-264, 1988.
3. Kaplan N.M.: The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 149: 1514-1520, 1989.
4. Fontbonne A., Eschwège E., Cambien F., Richard J.L., Ducimetière P., Thibult N., Warnet J.M., Claude J.R., Rosselin G.E.: Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32: 300-304, 1989.
5. Lento S., Ronnemaa T., Haffner S.M., Pyorala K., Kallio V., Laakso M.: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 48: 1354-1359, 1997.
6. United Kingdom Prospective Diabetes Study: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. B.M.J. 317: 703-713, 1998.
7. Eastman R.C., Javitt J.C., Herman W.H., Dasbach E.J., Copley Merriman C., Maier W., Dong F., Manninen D., Zbrozek A.S., Kotsanos J., Garfield S.A., Harris M.: Model of complications of NIDDM (II): analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20: 735-744, 1997.
8. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
9. Johannesson M., Jonsson B., Kjeskhus J., Olsson A.G., Pedersen T.R., Wedel H.: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary artery disease. Scandinavian Simvastatin Survival Study Group. N. Engl. J. Med. 336: 332-336, 1997.
10. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620, 1997.
11. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J., for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301-1307, 1995.
12. Sachs F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutheford J.D., Cole T.G., Brown L., Warnica J.W., Arnmold J.M.O., Wun C.-C., Davis B.R., Braunwald E., for the Cholesterol And Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335: 1001-1009, 1996.
13. Lea A.P., Mc Tavish D.: Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs: 828-847, 1997.
14. Wolffenbuttel B.H., Mahla G., Muller D., Pentrup A., Black D.M.: Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Neth. J. Med. 52: 131-137, 1998.
15. Black D.M., Bakker-Arkema R.G., Nawrocki J.W.: An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG.CoA reductase inhibitor. Arch. Intern. Med. 158:577-584, 1998.
16. Bakker-Arkerna R., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Kelison L.M., Brown V., Miller V.T., Shurzinske L.J., Black D.M.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J.A.M.A. 275: 128-133, 1996.
17. Stern R.H., Yang B.-B., Horton M., Moore S., Abel R.B., Olson S.C.: Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J. Clin. Pharmacol. 37: 816-819, 1997.
18. Stern R., Abel R., Gibson G.L., Besserer J.: Atorvastatin does not alter the anticoagulant activity of warfarin. J. Clin. Pharmacol. 37: 1062-1064, 1997.
19. Naumova R.P., Dunn S., Rallidis L., Abu-Muhana O., Neuwirth C., Rendel N.B., Taylor G.W., Thompson G.R.: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J. Lipid Res. 38: 1496-1500, 1997.
20. Nawrocki J.W., Weiss S.R., Havidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolernia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15: 678-682, 1995.
21. Dart A., Jerums G., Nicholson G., d'Emden M., Hamilton-Craig I., Tallis G., Best J., West M., Sullivan D., Bracs P., Black D.M.: A multicenter, double-blind one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol. 80: 39-44, 1997.
22. Davidson M., McKenney J., Stein E., Schrott H., Bakker-Arkema R., Fayyad R., Black D.: Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin study Group I. Am. J. Cardiol. 79: 1475-1481, 1997.
23. Schwartz W.W., Oliver M.F., Ezekovitz M.D., Ganz P., Waters D., Kane J.P., Texter M., Pressler M.L., Black D.M., Chaitman B.R., Olsson A.G.: Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am. J. Cardiol. 81: 578-581, 1998.
24. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A.: Effect of atorvastatin on plasma fibrinogen. Lancet 351: 569-570, 1997.
25. Brocco E., Fioretto P., Mauer M., Saller A., Carraro A., Frigato F., Chiesura-Corona M., Bianchi L., Baggio B., Maioli M., Abaterusso C., Velussi M., Sambataro M., Virgili F., Ossi E., Nosadini R.: Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int. 52 (Suppl. 63): S40-S44, 1997.